Cohort Studymoderate evidence
Individualized treatment effects of high flow nasal oxygen in immunocompromised patients.
Intensive care medicine·November 2, 2026·PMID 42970133
Why it mattersImmunocompromised patients with acute hypoxemic respiratory failure have high mortality and often require invasive mechanical ventilation, yet trials show no overall benefit from HFNO. Identifying which patients may benefit could guide personalized respiratory support and avoid unnecessary intubation or futile therapy.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled